Avexima plans to produce Nobazit therapy for coronavirus


Avexima pharmaceutical company has planned to organize production of antiviral drug Nobazit to combat coronavirus infection as part of the investment project in the Esipovo Industrial Park. This was reported in the press service of the Ministry of Investment, Industry and Science of the Moscow region.

“At the end of 2021, Avexima and the Moscow Region Development Corporation signed a supplementary agreement to expand the land plot for the project from 20 to 33 hectares, as well as to increase investments from 3 to 6.5 billion rubles. The number of jobs in the company will also grow, from 1,000 to 1,450. The investor plans to produce medicines, including anticancer drugs and antibiotics. In addition, due to the growing spread of coronavirus infection, the company has decided to additionally manufacture Nobazit, a drug against COVID-19, which will also be used to treat patients with the new omicron variant,” said Ekaterina Zinovieva, the head of the ministry.

According to the interim results of clinical trials, Nobazit provides a five-fold decline of the probability of death from coronavirus and two-fold decline the risk of pulmonary insufficiency. The drug is promising for the treatment of the new omicron strain of COVID-19 and an affordable product to prevent severe complications from SARS and influenza. The medicine is relevant on the eve of the season of colds and the next wave of the pandemic predicted by virologists.

Avexima pharmaceutical company was founded in 2011. It is one of the largest manufacturers of active pharmaceutical substances and finished pharmaceutical products in Russia. Today, the company produces more than 140 million packages of finished products annually. Its production potential is more than a billion packages per year, and the share in the segments of the medicines manufactured by the company medicines on the Russian market is 5.3%.